DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?

E. Smitskamp-Wilms, G. Giaccone, H. M. Pinedo, B. F A M van der Laan, G. J. Peters

Research output: Contribution to journalArticle

Abstract

DT-diaphorase (DTD) is an important enzyme for the bioreductive activation of the new alkylating indoloquinone E09. In preclinical studies, E09 has shown selective anti-tumour activity against solid tumours and under hypoxic conditions. The levels of three reductive enzymes have been determined in three types of human solid tumours, together with corresponding normal tissues and normal liver. DTD enzyme activities were measured in tumour extracts using 2,6-dichlorophenolindophenol (DCPIP) and NADH as substrates; cytochrome P450 reductase or cytochrome b5 reductase activities were assessed with cytochrome c and NADPH or NADH respectively. DTD activity was highest in non-small-cell lung (NSCLC) tumours (mean 123 nmol DCPIPmin-1mg-1), followed by colon carcinoma (mean 75 nmol min-1 mg-1) and squamous cell carcinoma of the head and neck (6-fold lower than NSCLC). DTD activity was very low in normal liver and normal lung (4-6 nmol min-1 mg-1), while the levels in normal colon mucosa or normal mucosa of the head and neck region were in the same range as the corresponding tumours. The levels of the two other reductive enzymes, cytochrome P450 reductase (CP450R) and cytochrome b5 reductase (Cb5R), were 5 to 25-fold lower than those of DTD in all the tissues, except for normal liver, in which DTD was 2 to 4-fold lower. The degree of variation found for DTD (range 4-250 nmol min-1 mg-1), was not observed for these enzymes (CP450R, 0.8-7.8 nmol cytochrome c min-1 mg-1; Cb5R, 3.5-27.6 nmol min-1 mg-1). It is anticipated that NSCLC patients are more likely to respond to E09 and other bioreductive agents, owing to the high levels of the activating enzyme in this tumour type. To prove that this assay has predictive value we need to study these enzyme levels in tumour samples obtained from patients on clinical studies with bioreductive agents.

Original languageEnglish (US)
Pages (from-to)917-921
Number of pages5
JournalBritish Journal of Cancer
Volume72
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

NAD(P)H Dehydrogenase (Quinone)
Cytochrome Reductases
Cytochromes b5
NADPH-Ferrihemoprotein Reductase
Neoplasms
Enzymes
NAD
Indolequinones
Liver
Colon
Mucous Membrane
2,6-Dichloroindophenol
Cytochromes c1
Lung
Enzyme Activation
Cytochromes c
NADP
Neck
Head
Carcinoma

Keywords

  • Bioreductive agents
  • Cytochrome b5 reductase
  • Cytochrome P450 reductase
  • DT-diaphorase
  • EO9
  • Head and neck squamous cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Smitskamp-Wilms, E., Giaccone, G., Pinedo, H. M., van der Laan, B. F. A. M., & Peters, G. J. (1995). DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? British Journal of Cancer, 72(4), 917-921.

DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? / Smitskamp-Wilms, E.; Giaccone, G.; Pinedo, H. M.; van der Laan, B. F A M; Peters, G. J.

In: British Journal of Cancer, Vol. 72, No. 4, 1995, p. 917-921.

Research output: Contribution to journalArticle

Smitskamp-Wilms, E, Giaccone, G, Pinedo, HM, van der Laan, BFAM & Peters, GJ 1995, 'DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?', British Journal of Cancer, vol. 72, no. 4, pp. 917-921.
Smitskamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BFAM, Peters GJ. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? British Journal of Cancer. 1995;72(4):917-921.
Smitskamp-Wilms, E. ; Giaccone, G. ; Pinedo, H. M. ; van der Laan, B. F A M ; Peters, G. J. / DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?. In: British Journal of Cancer. 1995 ; Vol. 72, No. 4. pp. 917-921.
@article{5c8f8bef112e4b75a926707a5676ed37,
title = "DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?",
abstract = "DT-diaphorase (DTD) is an important enzyme for the bioreductive activation of the new alkylating indoloquinone E09. In preclinical studies, E09 has shown selective anti-tumour activity against solid tumours and under hypoxic conditions. The levels of three reductive enzymes have been determined in three types of human solid tumours, together with corresponding normal tissues and normal liver. DTD enzyme activities were measured in tumour extracts using 2,6-dichlorophenolindophenol (DCPIP) and NADH as substrates; cytochrome P450 reductase or cytochrome b5 reductase activities were assessed with cytochrome c and NADPH or NADH respectively. DTD activity was highest in non-small-cell lung (NSCLC) tumours (mean 123 nmol DCPIPmin-1mg-1), followed by colon carcinoma (mean 75 nmol min-1 mg-1) and squamous cell carcinoma of the head and neck (6-fold lower than NSCLC). DTD activity was very low in normal liver and normal lung (4-6 nmol min-1 mg-1), while the levels in normal colon mucosa or normal mucosa of the head and neck region were in the same range as the corresponding tumours. The levels of the two other reductive enzymes, cytochrome P450 reductase (CP450R) and cytochrome b5 reductase (Cb5R), were 5 to 25-fold lower than those of DTD in all the tissues, except for normal liver, in which DTD was 2 to 4-fold lower. The degree of variation found for DTD (range 4-250 nmol min-1 mg-1), was not observed for these enzymes (CP450R, 0.8-7.8 nmol cytochrome c min-1 mg-1; Cb5R, 3.5-27.6 nmol min-1 mg-1). It is anticipated that NSCLC patients are more likely to respond to E09 and other bioreductive agents, owing to the high levels of the activating enzyme in this tumour type. To prove that this assay has predictive value we need to study these enzyme levels in tumour samples obtained from patients on clinical studies with bioreductive agents.",
keywords = "Bioreductive agents, Cytochrome b5 reductase, Cytochrome P450 reductase, DT-diaphorase, EO9, Head and neck squamous cell carcinoma",
author = "E. Smitskamp-Wilms and G. Giaccone and Pinedo, {H. M.} and {van der Laan}, {B. F A M} and Peters, {G. J.}",
year = "1995",
language = "English (US)",
volume = "72",
pages = "917--921",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?

AU - Smitskamp-Wilms, E.

AU - Giaccone, G.

AU - Pinedo, H. M.

AU - van der Laan, B. F A M

AU - Peters, G. J.

PY - 1995

Y1 - 1995

N2 - DT-diaphorase (DTD) is an important enzyme for the bioreductive activation of the new alkylating indoloquinone E09. In preclinical studies, E09 has shown selective anti-tumour activity against solid tumours and under hypoxic conditions. The levels of three reductive enzymes have been determined in three types of human solid tumours, together with corresponding normal tissues and normal liver. DTD enzyme activities were measured in tumour extracts using 2,6-dichlorophenolindophenol (DCPIP) and NADH as substrates; cytochrome P450 reductase or cytochrome b5 reductase activities were assessed with cytochrome c and NADPH or NADH respectively. DTD activity was highest in non-small-cell lung (NSCLC) tumours (mean 123 nmol DCPIPmin-1mg-1), followed by colon carcinoma (mean 75 nmol min-1 mg-1) and squamous cell carcinoma of the head and neck (6-fold lower than NSCLC). DTD activity was very low in normal liver and normal lung (4-6 nmol min-1 mg-1), while the levels in normal colon mucosa or normal mucosa of the head and neck region were in the same range as the corresponding tumours. The levels of the two other reductive enzymes, cytochrome P450 reductase (CP450R) and cytochrome b5 reductase (Cb5R), were 5 to 25-fold lower than those of DTD in all the tissues, except for normal liver, in which DTD was 2 to 4-fold lower. The degree of variation found for DTD (range 4-250 nmol min-1 mg-1), was not observed for these enzymes (CP450R, 0.8-7.8 nmol cytochrome c min-1 mg-1; Cb5R, 3.5-27.6 nmol min-1 mg-1). It is anticipated that NSCLC patients are more likely to respond to E09 and other bioreductive agents, owing to the high levels of the activating enzyme in this tumour type. To prove that this assay has predictive value we need to study these enzyme levels in tumour samples obtained from patients on clinical studies with bioreductive agents.

AB - DT-diaphorase (DTD) is an important enzyme for the bioreductive activation of the new alkylating indoloquinone E09. In preclinical studies, E09 has shown selective anti-tumour activity against solid tumours and under hypoxic conditions. The levels of three reductive enzymes have been determined in three types of human solid tumours, together with corresponding normal tissues and normal liver. DTD enzyme activities were measured in tumour extracts using 2,6-dichlorophenolindophenol (DCPIP) and NADH as substrates; cytochrome P450 reductase or cytochrome b5 reductase activities were assessed with cytochrome c and NADPH or NADH respectively. DTD activity was highest in non-small-cell lung (NSCLC) tumours (mean 123 nmol DCPIPmin-1mg-1), followed by colon carcinoma (mean 75 nmol min-1 mg-1) and squamous cell carcinoma of the head and neck (6-fold lower than NSCLC). DTD activity was very low in normal liver and normal lung (4-6 nmol min-1 mg-1), while the levels in normal colon mucosa or normal mucosa of the head and neck region were in the same range as the corresponding tumours. The levels of the two other reductive enzymes, cytochrome P450 reductase (CP450R) and cytochrome b5 reductase (Cb5R), were 5 to 25-fold lower than those of DTD in all the tissues, except for normal liver, in which DTD was 2 to 4-fold lower. The degree of variation found for DTD (range 4-250 nmol min-1 mg-1), was not observed for these enzymes (CP450R, 0.8-7.8 nmol cytochrome c min-1 mg-1; Cb5R, 3.5-27.6 nmol min-1 mg-1). It is anticipated that NSCLC patients are more likely to respond to E09 and other bioreductive agents, owing to the high levels of the activating enzyme in this tumour type. To prove that this assay has predictive value we need to study these enzyme levels in tumour samples obtained from patients on clinical studies with bioreductive agents.

KW - Bioreductive agents

KW - Cytochrome b5 reductase

KW - Cytochrome P450 reductase

KW - DT-diaphorase

KW - EO9

KW - Head and neck squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0028783332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028783332&partnerID=8YFLogxK

M3 - Article

C2 - 7547240

AN - SCOPUS:0028783332

VL - 72

SP - 917

EP - 921

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -